MRI在早期帕金森病诊断中的价值_West China Medical Journal

Authors：

廖悄 ¹ , 李楠楠 ¹ ,  彭蓉 ²

Corresponding author：

彭蓉, Email: liaoqiaoxy2008@yahoo.com.cn

Keywords：

帕金森病; 磁共振成像; 早期诊断

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

MRI因其无创性及对大脑解剖结构清晰的成像在神经系统变形疾病中得到广泛的应用。过去二十年中，功能性磁共振技术在常规MRI的基础上迅速发展起来。这些新的MRI技术提供大脑物质能量代谢、功能区体积测量和灌注等方面的信息，使得MRI在研究疾病的病理生理、分子学水平得到很大提高。现结合近几年国内外研究，对MRI在早期帕金森病诊断中的价值作一综述。

Citation： 廖悄,李楠楠,彭蓉. MRI在早期帕金森病诊断中的价值. West China Medical Journal, 2012, 27(11): 1733-1736. doi: Copy

1.	Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 300-318.
2.	Baudrexel S, Klein JC, Deichmann R, et al. Innovative MRI techniques in Parkinson’s disease[J]. Nervenarzt, 2010, 81(10): 1180-1188.
3.	Schuff N. Potential role of high-field MRI for studies in Parkinson’s disease[J]. Mov Disord, 2009, 24 Suppl 2(2): S684-S690.
4.	Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson’s disease by in vivo human brain imaging using 7.0T magnetic resonance imaging[J]. Mov Disord, 2011, 26(4): 713-718.
5.	Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord, 2003, 18(10): 1132-1138.
6.	Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease[J]. Neurosurgery, 2006, 58(2): 256-262.
7.	Borghammer P, Østergaard K, Cumming P, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease[J]. Eur J Neurol, 2010, 17(2): 314-320.
8.	Matthews PM, Jezzard P. Functional magnetic resonance imaging[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 6-12.
9.	Prodoehl J, Spraker M, Corcos D, et al. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease[J]. Mov Disord, 2010, 25(13): 2035-2043.
10.	Moraschi M, Giulietti G, Giove F, et al. fMRI study of motor cortex activity modulation in early Parkinson’s disease[J]. Magn Reson Imaging, 2010, 28(8): 1152-1158.
11.	Haacke EM, Ye Y. The role of susceptibility weighted imaging in functional MRI [J]. Neuroimage, 2012, 62(2): 923-929.
12.	Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease[J]. Mov Disord, 2011, 26(6): 1049-1055.
13.	Hill JM, Ruff MR, Weber RJ, et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to Iron distribution[J]. Proc Natl Acad Sci U S A, 1985, 82(13): 4553-4557.
14.	Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease[J]. J Magn Reson Imaging, 2012, 35(1): 48-55.
15.	Zhang W, Sun SG, Jiang YH, et al. Determination of brain Iron content in patients with Parkinson’s disease using magnetic susceptibility imaging[J]. Neurosci Bull, 2009, 25(6): 353-360.
16.	Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson’s disease[J]. Neuroimage, 2004, 21(4): 1443-1451.
17.	Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease[J]. Brain, 2006, 129(Pt 2): 538-542.
18.	Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease[J]. J Neurol, 2011, 258(7): 1254-1260.
19.	Gaudiello F, Garaci FG, Marziali S, et al. Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson’s disease[J]. Radiol Med, 2006, 111(2): 284-290.
20.	Melzer TR, Watts R, Macaskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease[J]. Brain, 2011, 134(Pt 3): 845-855.
21.	Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson’s disease and parkinsonian syndromes[J]. Funct Neurol, 2007, 22(2): 75-79.
22.	Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease[J]. Brain, 2009, 132(Pt 12): 3285-3297.
23.	Michell AW, Lewis SG, Foltynie T, et al. Biomarkers and parkinson’s disease[J]. Brain, 2004, 127(8): 1693-1705.
24.	Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients[J]. Neurol Sci, 2001, 22(1): 69-70.
25.	Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism[J]. Neuroradiology, 2010, 52(12): 1087-1094.
26.	Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI[J]. Nervenarzt, 2010, 81(10): 1168-1179.
27.	Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy[J]. Neurology, 2003, 60(6): 922-927.
28.	Boelmans K, Bodammer NC, Suchorska B, et al. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease[J]. Parkinsonism Relat Disord, 2010, 16(8): 498-502.
29.	Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD[J]. Neurology, 2002, 58(4): 575-580.
30.	Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson’s disease and progressive supranuclear palsy[J]. Brain, 2006, 129(Pt 10): 2679-2687.

1. 　Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 300-318.
2. 　Baudrexel S, Klein JC, Deichmann R, et al. Innovative MRI techniques in Parkinson’s disease[J]. Nervenarzt, 2010, 81(10): 1180-1188.
3. 　Schuff N. Potential role of high-field MRI for studies in Parkinson’s disease[J]. Mov Disord, 2009, 24 Suppl 2(2): S684-S690.
4. 　Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson’s disease by in vivo human brain imaging using 7.0T magnetic resonance imaging[J]. Mov Disord, 2011, 26(4): 713-718.
5. 　Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord, 2003, 18(10): 1132-1138.
6. 　Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease[J]. Neurosurgery, 2006, 58(2): 256-262.
7. 　Borghammer P, Østergaard K, Cumming P, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease[J]. Eur J Neurol, 2010, 17(2): 314-320.
8. 　Matthews PM, Jezzard P. Functional magnetic resonance imaging[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 6-12.
9. 　Prodoehl J, Spraker M, Corcos D, et al. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease[J]. Mov Disord, 2010, 25(13): 2035-2043.
10. 　Moraschi M, Giulietti G, Giove F, et al. fMRI study of motor cortex activity modulation in early Parkinson’s disease[J]. Magn Reson Imaging, 2010, 28(8): 1152-1158.
11. 　Haacke EM, Ye Y. The role of susceptibility weighted imaging in functional MRI [J]. Neuroimage, 2012, 62(2): 923-929.
12. 　Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease[J]. Mov Disord, 2011, 26(6): 1049-1055.
13. 　Hill JM, Ruff MR, Weber RJ, et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to Iron distribution[J]. Proc Natl Acad Sci U S A, 1985, 82(13): 4553-4557.
14. 　Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease[J]. J Magn Reson Imaging, 2012, 35(1): 48-55.
15. 　Zhang W, Sun SG, Jiang YH, et al. Determination of brain Iron content in patients with Parkinson’s disease using magnetic susceptibility imaging[J]. Neurosci Bull, 2009, 25(6): 353-360.
16. 　Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson’s disease[J]. Neuroimage, 2004, 21(4): 1443-1451.
17. 　Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease[J]. Brain, 2006, 129(Pt 2): 538-542.
18. 　Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease[J]. J Neurol, 2011, 258(7): 1254-1260.
19. 　Gaudiello F, Garaci FG, Marziali S, et al. Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson’s disease[J]. Radiol Med, 2006, 111(2): 284-290.
20. 　Melzer TR, Watts R, Macaskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease[J]. Brain, 2011, 134(Pt 3): 845-855.
21. 　Rango M, Arighi A, Biondetti P, et al. Magnetic resonance spectroscopy in Parkinson’s disease and parkinsonian syndromes[J]. Funct Neurol, 2007, 22(2): 75-79.
22. 　Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease[J]. Brain, 2009, 132(Pt 12): 3285-3297.
23. 　Michell AW, Lewis SG, Foltynie T, et al. Biomarkers and parkinson’s disease[J]. Brain, 2004, 127(8): 1693-1705.
24. 　Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients[J]. Neurol Sci, 2001, 22(1): 69-70.
25. 　Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism[J]. Neuroradiology, 2010, 52(12): 1087-1094.
26. 　Mahlknecht P, Schocke M, Seppi K. Differential diagnosis of parkinsonian syndromes using MRI[J]. Nervenarzt, 2010, 81(10): 1168-1179.
27. 　Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy[J]. Neurology, 2003, 60(6): 922-927.
28. 　Boelmans K, Bodammer NC, Suchorska B, et al. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease[J]. Parkinsonism Relat Disord, 2010, 16(8): 498-502.
29. 　Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD[J]. Neurology, 2002, 58(4): 575-580.
30. 　Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson’s disease and progressive supranuclear palsy[J]. Brain, 2006, 129(Pt 10): 2679-2687.

West China Medical Journal

MRI在早期帕金森病诊断中的价值

Abstract Full text Figures/Tables Video References Cited by

Format

Content